MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. HTFL
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Heartflow (HTFL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Heartflow
NasdaqGS•Healthcare•Health Information Services
$48.30-0.03(<0.01%)Pre-market
Market Cap
$4.38B
P/S
17.6x
P/B
15.7x

HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.

D

How this company scores

WeakMetricSide Score: 36/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (4/25).

Profitability7/25
Growth10/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality4/25
Strengths
Interest easily coveredConsistent growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 17.6x5y range 8.9x – 17.6x
P/S 17.6x
P/B · 15.7x5y range 3.7x – 15.7x
P/B 15.7x · above its 4-quarter median

Currently above its 4-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 5 of the last 5 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $4.38B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$249.28M
2Q
Q. Revenue
$64.08M
48%
TTM EBITDA
$-88.37M
2Q
TTM Op. Income
$-97.75M
2Q
Q. Op. Income
$-17.90M
2Q
TTM Net Income
$-150.72M
2Q
Q. Net Income
$-15.74M
2Q
EPS
$-0.18
2Q
Shares Out.
$86.40M
2Q
$249.28M in TTM revenue grew from zero YoY, reaching $64.08M last quarter. TTM EBITDA of $-88.37M and TTM operating income of $-97.75M show growth is flowing through to the bottom line. However, net income is negative at $150.72M — growth is not yet reaching the bottom line. Across the last 5 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
83.0%
4Q
EBITDA Margin
-26.0%
3%
Op. Margin
-27.9%
12%
Net Margin
-24.6%
3Q
Op. margin of -27.9% is up 3.7% YoY — cost efficiency is improving. Net margin at -24.6% and gross margin of 83.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 12% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
17.6x
P/B Ratio
15.7x
2Q
P/S of 17.6x and P/B of 15.7x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$344.46M
116%
Cash
$34.36M
57%
Long-Term Debt
N/A
Book Value
$279.73M
2Q
D/E Ratio
N/A
Debt/EBITDA
N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$-8.58M
79%
TTM Free Cash Flow
$-59.18M
FCF Margin
-23.7%
FCF / Net Income
0.4
TTM FCF of $-59.18M on $-8.58M in operating cash flow. The FCF / Net Income ratio of 0.4x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 0% — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Cash Burn

Red Flag

The last 5 consecutive quarters had negative FCF — the company is burning cash and may need external funding.

Share Dilution

Red Flag

Shares outstanding increased 1267.9% — significant dilution, likely from stock compensation or capital raises.